Modality
Peptide
MOA
JAK1i
Target
KRASG12D
Pathway
T-cell
RB
Development Pipeline
Preclinical
Mar 2021
→ Dec 2030
PreclinicalCurrent
NCT07114075
2,069 pts·RB
2021-03→2030-12·Completed
NCT04673475
90 pts·RB
2025-10→2030-02·Not yet recruiting
2,159 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-02-193.9y awayInterim· RB
2030-12-244.7y awayInterim· RB
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Complet…
Preclinical
Not yet…
Catalysts
Interim
2030-02-19 · 3.9y away
RB
Interim
2030-12-24 · 4.7y away
RB
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07114075 | Preclinical | RB | Completed | 2069 | BodyWt |
| NCT04673475 | Preclinical | RB | Not yet recr... | 90 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 |